Caladrius Biosciences (CLBS) Stock Price, News & Analysis

Company Overview

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.43 to $8.38
• 52-Week Range: N/A
• Volume: 466,373 shs
• Average Volume: 522,308 shs
• Market Capitalization: $26.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLBS Stock Analysis - Frequently Asked Questions

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences, Inc. (NASDAQ:CLBS) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.95) by $0.15.

When did Caladrius Biosciences' stock split?

Caladrius Biosciences's stock reverse split before market open on Thursday, September 15th 2022.The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Caladrius Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Caladrius Biosciences investors own include Meta Platforms (META), Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Alphabet (GOOG), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Miscellaneous Health & Allied Services
• Sub-Industry: N/A
• Current Symbol: NASDAQ:CLBS
• CIK: 320017
• Web: www.caladrius.com
• Phone: (908) 842-0100
• Fax: 646-514-7787
• Employees: 27
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): ($0.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$27.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -27.24%
• Return on Assets: -26.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.33
• Quick Ratio: 22.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.54 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 60,583,000
• Free Float: 59,250,000
• Market Cap: $26.05 million
• Optionable: Optionable
• Beta: 0.91